Saisun Pharma Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
- Paid Up Capital ₹ 1.00 M
- Company Age 21 Year, 7 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 12.38 Cr
- Revenue Growth 24.08%
- Profit Growth 34.47%
- Ebitda 741.62%
- Net Worth 16.89%
- Total Assets -2.28%
About Saisun Pharma
Saisun Pharma Private Limited (SPPL) is a leading Private Limited Indian Non-Government Company incorporated in India on 27 June 2003 and has a history of 21 years and seven months. Its registered office is in Delhi, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 1.00 M.
The company currently has active open charges totaling ₹12.38 Cr.
Sanal Kuttikkat and Nyapati Giridhar serve as directors at the Company.
Company Details
-
Location
Delhi, India
-
Telephone
+91-XXXXXXXXXX
- Email Address
-
Website
-
-
Social Media
-
Corporate Identity Details
-
CIN/LLPIN
U24231DL2003PTC121103
-
Company No.
121103
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
27 Jun 2003
-
Date of AGM
30 Sep 2024
-
Date of Balance Sheet
31 Mar 2024
-
Listing Status
Unlisted
-
ROC Code
Roc Delhi
Industry
Who are the key members and board of directors at Saisun Pharma?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Nyapati Giridhar
|
Director | 27-Jun-2003 | Current |
|
Sanal Kuttikkat
|
Director | 01-Apr-2005 | Current |
Financial Performance of Saisun Pharma.
Saisun Pharma Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 24.08% increase. The company also saw a substantial improvement in profitability, with a 34.47% increase in profit. The company's net worth Soared by an impressive increase of 16.89%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Saisun Pharma?
In 2023, Saisun Pharma had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
-
Aaspada Enterprises Private LimitedSanal Kuttikkat and Nyapati Giridhar are mutual person
-
Erotas Life Sciences Private Limited
Nyapati Giridhar is a mutual person
Charges (Loans)
₹123.80 M
₹0
Charges Breakdown by Lending Institutions
- Others : 10.16 Cr
- Idbi Bank Limited : 2.22 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 13 Sep 2024 | Others | ₹10.00 Cr | Open |
| 30 Mar 2024 | Idbi Bank Limited | ₹6.50 M | Open |
| 18 Feb 2022 | Others | ₹1.60 M | Open |
| 04 May 2013 | Idbi Bank Limited | ₹1.57 Cr | Open |
How Many Employees Work at Saisun Pharma?
Saisun Pharma has a workforce of 3 employees as of Apr 04, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Saisun Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Saisun Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
